Nebivolol induces distinct changes in profibrosis MicroRNA expression compared with atenolol, in salt-sensitive hypertensive rats

Hongmei Ye, Shukuan Ling, Alexander C. Castillo, Bejoy Thomas, Bo Long, Jinqiao Qian, Jose R. Perez-Polo, Yumei Ye, Xiaoping Chen, Yochai Birnbaum

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Nebivolol is a selective β1-blocker with nitric oxide-enhancing effects. MicroRNAs are small noncoding RNA molecules that downregulate gene expression. We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension. Dahl salt-sensitive rats received either low-salt chow (control) or AIN-76A high-salt (8% NaCl) diet and randomized to vehicle (high-salt), nebivolol (20 mg/kg per day), or atenolol (50 mg/kg per day) for 8 weeks. High-salt induced left ventricular hypertrophy and fibrosis and decreased the expression of miR-27a,-29a, and-133a. Nebovolol attenuated deterioration of left ventricular systolic function, remodeling, and fibrosis more than atenolol, despite similar effects on heart rate and blood pressure. Nebivolol, but not atenolol, prevented the decrease in miR-27a and-29a induced by high-salt. Nebivolol and atenolol equally attenuated the decrease in miR-133a. In vitro overexpression of miR-27a,-29a, and-133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. Both miR-27a and-29a target Sp1, and miR-133a targets Cdc42. Pharmacological inhibition of Sp1 and Cdc42 decreased myocardial fibrosis and hypertrophy. Our data support a differential microRNAs expression profile in salt-induced hypertension. Nebivolol substantially attenuated cardiac remodeling, hypertrophy, and fibrosis more than atenolol. These effects are related to attenuation of the hypertension-induced decrease in miR-27a and-29a (with a subsequent decrease in Sp1 expression) and miR-133a (with a subsequent decrease in Cdc42).

Original languageEnglish (US)
Pages (from-to)1008-1013
Number of pages6
JournalHypertension
Volume61
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Nebivolol
Atenolol
MicroRNAs
Salts
Fibrosis
Left Ventricular Hypertrophy
Hypertension
Left Ventricular Function
Hypertrophy
Inbred Dahl Rats
Small Untranslated RNA
Cardiomegaly
Cardiac Myocytes
Rodentia
Nitric Oxide
Collagen
Down-Regulation
Heart Rate
Pharmacology
Diet

Keywords

  • β-blocker
  • fibrosis
  • hypertension
  • microRNA
  • remodeling

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Nebivolol induces distinct changes in profibrosis MicroRNA expression compared with atenolol, in salt-sensitive hypertensive rats. / Ye, Hongmei; Ling, Shukuan; Castillo, Alexander C.; Thomas, Bejoy; Long, Bo; Qian, Jinqiao; Perez-Polo, Jose R.; Ye, Yumei; Chen, Xiaoping; Birnbaum, Yochai.

In: Hypertension, Vol. 61, No. 5, 05.2013, p. 1008-1013.

Research output: Contribution to journalArticle

Ye, H, Ling, S, Castillo, AC, Thomas, B, Long, B, Qian, J, Perez-Polo, JR, Ye, Y, Chen, X & Birnbaum, Y 2013, 'Nebivolol induces distinct changes in profibrosis MicroRNA expression compared with atenolol, in salt-sensitive hypertensive rats', Hypertension, vol. 61, no. 5, pp. 1008-1013. https://doi.org/10.1161/HYPERTENSIONAHA.111.00892
Ye, Hongmei ; Ling, Shukuan ; Castillo, Alexander C. ; Thomas, Bejoy ; Long, Bo ; Qian, Jinqiao ; Perez-Polo, Jose R. ; Ye, Yumei ; Chen, Xiaoping ; Birnbaum, Yochai. / Nebivolol induces distinct changes in profibrosis MicroRNA expression compared with atenolol, in salt-sensitive hypertensive rats. In: Hypertension. 2013 ; Vol. 61, No. 5. pp. 1008-1013.
@article{81cfc389213b42858ae96562039427ba,
title = "Nebivolol induces distinct changes in profibrosis MicroRNA expression compared with atenolol, in salt-sensitive hypertensive rats",
abstract = "Nebivolol is a selective β1-blocker with nitric oxide-enhancing effects. MicroRNAs are small noncoding RNA molecules that downregulate gene expression. We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension. Dahl salt-sensitive rats received either low-salt chow (control) or AIN-76A high-salt (8{\%} NaCl) diet and randomized to vehicle (high-salt), nebivolol (20 mg/kg per day), or atenolol (50 mg/kg per day) for 8 weeks. High-salt induced left ventricular hypertrophy and fibrosis and decreased the expression of miR-27a,-29a, and-133a. Nebovolol attenuated deterioration of left ventricular systolic function, remodeling, and fibrosis more than atenolol, despite similar effects on heart rate and blood pressure. Nebivolol, but not atenolol, prevented the decrease in miR-27a and-29a induced by high-salt. Nebivolol and atenolol equally attenuated the decrease in miR-133a. In vitro overexpression of miR-27a,-29a, and-133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. Both miR-27a and-29a target Sp1, and miR-133a targets Cdc42. Pharmacological inhibition of Sp1 and Cdc42 decreased myocardial fibrosis and hypertrophy. Our data support a differential microRNAs expression profile in salt-induced hypertension. Nebivolol substantially attenuated cardiac remodeling, hypertrophy, and fibrosis more than atenolol. These effects are related to attenuation of the hypertension-induced decrease in miR-27a and-29a (with a subsequent decrease in Sp1 expression) and miR-133a (with a subsequent decrease in Cdc42).",
keywords = "β-blocker, fibrosis, hypertension, microRNA, remodeling",
author = "Hongmei Ye and Shukuan Ling and Castillo, {Alexander C.} and Bejoy Thomas and Bo Long and Jinqiao Qian and Perez-Polo, {Jose R.} and Yumei Ye and Xiaoping Chen and Yochai Birnbaum",
year = "2013",
month = "5",
doi = "10.1161/HYPERTENSIONAHA.111.00892",
language = "English (US)",
volume = "61",
pages = "1008--1013",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Nebivolol induces distinct changes in profibrosis MicroRNA expression compared with atenolol, in salt-sensitive hypertensive rats

AU - Ye, Hongmei

AU - Ling, Shukuan

AU - Castillo, Alexander C.

AU - Thomas, Bejoy

AU - Long, Bo

AU - Qian, Jinqiao

AU - Perez-Polo, Jose R.

AU - Ye, Yumei

AU - Chen, Xiaoping

AU - Birnbaum, Yochai

PY - 2013/5

Y1 - 2013/5

N2 - Nebivolol is a selective β1-blocker with nitric oxide-enhancing effects. MicroRNAs are small noncoding RNA molecules that downregulate gene expression. We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension. Dahl salt-sensitive rats received either low-salt chow (control) or AIN-76A high-salt (8% NaCl) diet and randomized to vehicle (high-salt), nebivolol (20 mg/kg per day), or atenolol (50 mg/kg per day) for 8 weeks. High-salt induced left ventricular hypertrophy and fibrosis and decreased the expression of miR-27a,-29a, and-133a. Nebovolol attenuated deterioration of left ventricular systolic function, remodeling, and fibrosis more than atenolol, despite similar effects on heart rate and blood pressure. Nebivolol, but not atenolol, prevented the decrease in miR-27a and-29a induced by high-salt. Nebivolol and atenolol equally attenuated the decrease in miR-133a. In vitro overexpression of miR-27a,-29a, and-133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. Both miR-27a and-29a target Sp1, and miR-133a targets Cdc42. Pharmacological inhibition of Sp1 and Cdc42 decreased myocardial fibrosis and hypertrophy. Our data support a differential microRNAs expression profile in salt-induced hypertension. Nebivolol substantially attenuated cardiac remodeling, hypertrophy, and fibrosis more than atenolol. These effects are related to attenuation of the hypertension-induced decrease in miR-27a and-29a (with a subsequent decrease in Sp1 expression) and miR-133a (with a subsequent decrease in Cdc42).

AB - Nebivolol is a selective β1-blocker with nitric oxide-enhancing effects. MicroRNAs are small noncoding RNA molecules that downregulate gene expression. We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension. Dahl salt-sensitive rats received either low-salt chow (control) or AIN-76A high-salt (8% NaCl) diet and randomized to vehicle (high-salt), nebivolol (20 mg/kg per day), or atenolol (50 mg/kg per day) for 8 weeks. High-salt induced left ventricular hypertrophy and fibrosis and decreased the expression of miR-27a,-29a, and-133a. Nebovolol attenuated deterioration of left ventricular systolic function, remodeling, and fibrosis more than atenolol, despite similar effects on heart rate and blood pressure. Nebivolol, but not atenolol, prevented the decrease in miR-27a and-29a induced by high-salt. Nebivolol and atenolol equally attenuated the decrease in miR-133a. In vitro overexpression of miR-27a,-29a, and-133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. Both miR-27a and-29a target Sp1, and miR-133a targets Cdc42. Pharmacological inhibition of Sp1 and Cdc42 decreased myocardial fibrosis and hypertrophy. Our data support a differential microRNAs expression profile in salt-induced hypertension. Nebivolol substantially attenuated cardiac remodeling, hypertrophy, and fibrosis more than atenolol. These effects are related to attenuation of the hypertension-induced decrease in miR-27a and-29a (with a subsequent decrease in Sp1 expression) and miR-133a (with a subsequent decrease in Cdc42).

KW - β-blocker

KW - fibrosis

KW - hypertension

KW - microRNA

KW - remodeling

UR - http://www.scopus.com/inward/record.url?scp=84876672015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876672015&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.111.00892

DO - 10.1161/HYPERTENSIONAHA.111.00892

M3 - Article

C2 - 23460283

AN - SCOPUS:84876672015

VL - 61

SP - 1008

EP - 1013

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 5

ER -